anti-CD45 antibody-drug conjugate (Magenta Therapeutics)

N/A

Report date: 2025/06/11 11:06:14

Base Information

Drug Nameanti-CD45 antibody-drug conjugate (Magenta Therapeutics)
Drug Alias NameCD45-ADCMGTA-45MGTA-C100
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionImmunomodulatorsLeukocyte common antigen inhibitors
TargetsLeukocyte common antigen
Therapy Area/IndicationsAutoimmune DiseasesAtherosclerosisLeukemia, Myeloid, Acute +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMagenta Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesMagenta Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesLeukemia, Myeloid, AcuteHematopoietic stem cell transplantation (HSCT)
Inactive IndicationsAtherosclerosis

Other Information

ATC CodeN/A
Related LinksN/A